Enliven Therapeutics (NASDAQ:ELVN) Given New $40.00 Price Target at Robert W. Baird

Enliven Therapeutics (NASDAQ:ELVN) had its target price hoisted by stock analysts at Robert W. Baird from $32.00 to $40.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target points to a potential upside of 60.51% from the stock’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Stock Down 3.4 %

Shares of ELVN stock opened at $24.92 on Friday. The business has a 50-day moving average price of $26.16 and a two-hundred day moving average price of $23.88. The firm has a market cap of $1.18 billion, a P/E ratio of -13.12 and a beta of 1.08. Enliven Therapeutics has a 12-month low of $9.80 and a 12-month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, research analysts expect that Enliven Therapeutics will post -1.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $22.89, for a total value of $274,680.00. Following the completion of the transaction, the chief executive officer now directly owns 1,049,255 shares of the company’s stock, valued at $24,017,446.95. The trade was a 1.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock in a transaction on Monday, October 28th. The shares were sold at an average price of $28.56, for a total value of $178,500.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 152,195 shares of company stock valued at $4,091,454. Insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC raised its position in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after buying an additional 3,559 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics in the first quarter valued at about $167,000. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics during the third quarter worth about $256,000. Finally, Verition Fund Management LLC acquired a new position in shares of Enliven Therapeutics during the third quarter valued at $271,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.